Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide for MRD in AML/MDS Post-Allo-HCT
NCT02370888Phase 1Terminated
- Sponsor
- University of Florida
- Start
- May 2016
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lenalidomide in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by University of Florida. Primary endpoint: Maximum Tolerated Dose up to 72 days. Started May 2016; status: terminated.
02
Drugs
lenalidomide
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02370888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02370888.